Phase 3RecruitingPriority 1 · Highest priorityNCT07300514
Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma
Plain-language summary
This Phase 3 trial is comparing different first-line treatment approaches for people newly diagnosed with a type of T-cell lymphoma called AITL. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.
Who can join (key eligibility)
- Age 18 Years or older
- Newly diagnosed, not yet treated
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
PET-CTandct- DNAdetection (DEVICE): The patients who achieved CMR by PET-CT and MRD-neg by ct-DNA testing were evaluated at 12 months,One patient stopped maintenance treatment, while the rest continued for one year. | golidocitinib (DRUG): golidocitinib maintenance treatment given orally as 150mg every other day | Placebo (DRUG): Placebo given orally as 150mg every other day
- Drugs / treatments
- PET-CTandct- DNAdetection, golidocitinib, Placebo
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details